Phio Pharmaceuticals
PHIO
24 hedge funds and large institutions have $663K invested in Phio Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 24 → 24 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.18% less ownership
Funds ownership: 5.75% → 5.57% (-0.18%)
19% less capital invested
Capital invested by funds: $815K → $663K (-$152K)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMI
Nomura Asset Management International
Philadelphia,
Pennsylvania
|
+$57K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$53.7K |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$16.4K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$13.7K |
| 5 |
Citigroup
New York
|
+$12.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$37.2K |
| 2 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$36.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$24.6K |
| 4 |
HF
HRT Financial
New York
|
-$24.6K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$24K |
PHIO Hedge Fund Activity: Q2 2026 in Review
24 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2026, worth a combined $663K — down 19% from $815K a quarter earlier.
Fund positioning in PHIO was balanced in Q2 2026: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 8 trimmed.
The largest buyer was Nomura Asset Management International, opening a new position worth an estimated $57K. The largest seller was Geode Capital Management, cutting an estimated $37.2K.
- 24 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $663K of Phio Pharmaceuticals stock for Q2 2026, down 19% quarter-over-quarter.
- 4 funds opened new Phio Pharmaceuticals positions in Q2 2026 and 4 closed out, a net change of 0 holders.
- The largest Phio Pharmaceuticals buyer in Q2 2026 was Nomura Asset Management International, an estimated $57K added.
- The largest Phio Pharmaceuticals seller in Q2 2026 was Geode Capital Management, an estimated $37.2K sold.
Based on aggregated 13F filings for Q2 2026.